Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · NATHBIOGEN

NATH BIOGEN

Fast Moving Consumer GoodsAgricultural Food & other Products₹255 cr market cap
₹133.02 ▼ -0.46% today As of 19 Nov 2026
52-week low ₹129.0252-week high ₹196.01

-31.8% from the 52-week high · +3.6% above the low

Nath Bio-Genes (India) Ltd. engages in the production and marketing of seeds. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2014-01-28. The firm is engaged in the Seed Cultivation segment. The Company’s products categories include oilseeds and fiber, field crops, vegetables and plant nutrition. Its fiber and oils seeds include cotton and mustard. The firm's vegetable crop range includes chili, okra, tomato, bottle gourd, bitter gourd, cucumber, coriander, pumpkin, tinda and others. Its field corps include corn, jowar, hybrid paddy, research paddy and wheat. Its plant nutrition products include WINPro GOLii, WINall and Win Chin Win. Its forage products include NUTRIMAX and NUTRIMAX GOLD. The firm has seed processing facilities processing plants located in Maharashtra, Telangana and Andhra Pradesh. The firm also has processing arrangements in Gujarat, Karnataka, Tamil Nadu, Madhya Pradesh and Rajasthan on custom basis.

The short version. NATH BIOGEN reported revenue of ₹41 crore for Sep 2026, down 6.8% from a year earlier. Net profit was ₹0 crore (down 100.0% year on year). Return on equity was 6.1% in Mar 2026. Promoter holding was 45.6% in Sep 2026, up 0.00 points over 8 quarters.

1 · The price

How has the stock traded?

NATH BIOGEN trades 31.8% below its 52-week high and 3.6% above its 52-week low.

Change over period: —

1M-1.5%
3M-13.1%
6M-19.9%
1Y-18.3%

2 · The business

Is it growing?

Sales, year on year-6.8%

Sep 2026 revenue of ₹41 cr.

Net margin1.0%

5.3 pts lower than a year earlier.

3-year growth5.9% profit

Revenue compounded at 14.5% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue413285266442845237
Net profit0320233713
Net margin %1.09.8-0.02.46.313.12.87.2
EPS (₹)0.2216.980.00.841.4519.620.781.39

Annual

FY2026FY2025FY2024FY2023
Revenue445365333301
Net profit42394035
Net margin %9.410.611.911.6
EPS (₹)21.9120.3120.8518.43

3 · The quality

How well does it turn capital into profit?

Return on equity was 6.1% in Mar 2026; debt to equity is 0.20.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %6.16.06.56.1
Return on capital %8.97.78.28.0
EBITDA margin %14.614.916.216.3
Net margin %9.210.411.911.6

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR14.5%—
Profit CAGR5.9%—
Debt to equity0.20
Interest cover3.9x
Current ratio1.97
P/E ratio7.0

4 · The owners

Who holds it, and are they adding?

Promoter holding45.6%

Unchanged over 8 quarters.

Foreign institutions0.19%

Unchanged over 8 quarters.

Domestic institutions0.01%

Down 4.36 pts over 8 quarters.

Mutual fund schemes0

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter45.645.645.645.645.645.645.645.60.0
FII0.190.210.420.320.310.230.270.190.0
DII4.373.942.250.760.010.010.010.01-4.36
Public49.8450.2551.7453.3254.0854.1754.1354.21+4.37

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for NATH BIOGEN are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about NATH BIOGEN

What is the NATH BIOGEN share price?

NATH BIOGEN (NATHBIOGEN) last closed at ₹133.02, down 0.46% on the day. Its 52-week range is ₹129.02 to ₹196.01.

What is the market cap of NATH BIOGEN?

NATH BIOGEN has a market capitalisation of about ₹255 crore. Its price-to-earnings ratio is 7.0.

How are NATH BIOGEN's latest results?

NATH BIOGEN reported revenue of ₹41 crore for Sep 2026, down 6.8% from a year earlier. Net profit was ₹0 crore (down 100.0% year on year). Return on equity was 6.1% in Mar 2026. Promoter holding was 45.6% in Sep 2026, up 0.00 points over 8 quarters.

Who owns NATH BIOGEN?

As of Sep 2026, shareholding was: Promoter 45.6%, FII 0.19%, DII 0.01%, Public 54.21%.

How many mutual funds hold NATH BIOGEN?

0 mutual fund schemes held NATH BIOGEN in October 2026. That compares with 0 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 14 Aug 2025 · Final Dividend - Rs. 2
  • 09 Aug 2024 · Final Dividend - Rs. 2
  • 04 Jul 2023 · Final Dividend - Rs. 2
  • 23 Jun 2022 · Dividend - Rs. 2
  • 18 Aug 2021 · Final Dividend - Rs. 2

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.